Elsevier

Leukemia Research

Volume 34, Issue 8, August 2010, Pages 969-973
Leukemia Research

Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations

https://doi.org/10.1016/j.leukres.2010.02.033Get rights and content

Abstract

While a majority of patients with refractory anemia with ring sideroblasts and thrombocytosis harbor JAK2V617F and rarely MPLW515L, JAK2/MPL-negative cases constitute a diagnostic problem. 23 RARS-T cases were investigated applying immunohistochemical phospho-STAT5, sequencing and SNP-A-based karyotyping. Based on the association of TET2/ASXL1 mutations with MDS/MPN we studied molecular pattern of these genes. Two patients harbored ASXL1 and another 2 TET2 mutations. Phospho-STAT5 activation was present in one mutated TET2 and ASXL1 case. JAK2V617F/MPLW515L mutations were absent in TET2/ASXL1 mutants, indicating that similar clinical phenotype can be produced by various MPN-associated mutations and that additional unifying lesions may be present in RARS-T.

Introduction

Refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) has been considered a provisional subtype within the diagnostic entity of myelodysplastic/myeloproliferative neoplasms (MDS/MPN). As the JAK2 V617F mutation is present in a significant proportion of RARS-T patients [1], [2], [3], [4], [5], [6], [7], many investigators consider this entity to be more closely related to MPN, as reflected in the newest version of the 2008 revised WHO classification of myeloid neoplasms [8]. Some cases of RARS-T revealed the MPL W515L mutation typical for classical MPN [9], [10]. In addition, we have previously postulated that an aberrant STAT5 phosphorylation pattern may be a characteristic feature of true RARS-T, while negative cases may result from an unrelated etiology [11]. Consequently, a significant minority of patients with RARS-T that does not harbor JAK2/MPL mutations may simply represent RARS cases with other thrombocytosis-inducing conditions, or be due to unrelated molecular lesions producing a similar phenotype. Conversely, morphologically indistinguishable phenotypes may be due to different gene mutations functionally connected by convergent networks.

Using single nucleotide polymorphism (SNP) arrays we have recently observed a frequent area of somatic uniparental disomy (UPD) at 4q24, most commonly encountered in patients with chronic myelomonocytic leukemia (CMML), mixed MDS/MPN, some typical MDS, secondary acute myeloid leukemia (sAML) and one report on RARS-T [12], [13], [14], [15], [16], [17], [18]. Overlapping microdeletions on 4q24 pointed towards the TET2 gene, in which mutations were identified by us and other groups in different myeloid malignancies, most significantly MPN and MDS/MPN [15], [16], [19]. Recent studies have also identified mutations of ASXL1 (additional sex combs like 1) gene in MDS and MPN [20], [21] that is located in the chromosomal region 20q11. ASXL1, along with TET2, is a member of WNT pathway and possibly regulates histone modifications [21]. Based on the association with MDS/MPN, and the established correlation of RARS-T with JAK2 V617F and MPL W515L mutations, we therefore sought to evaluate the mutational status of TET2 and ASXL1 in RARS-T patients.

Section snippets

Patients

Bone marrow and blood samples were collected from 23 patients with RARS-T. Informed consent was obtained according to protocols approved by the IRB of the Cleveland Clinic. The RARS-T patient characteristics are presented in Table 1. Metaphase cytogenetic (MC) analysis was performed on marrow aspirates according to standard methods.

DNA extraction

The Genomic DNA Purification Kit (Gentra Systems, Inc., MN) was used for DNA isolation according to manufacturer instruction.

TET2 and ASXL1 sequencing. JAK2 V617F and MPL W515L mutation detection by ARMS-PCR

The status of the JAK2 V617F and MPL

Results and discussion

The previously reported cohort of 20 patients with RARS-T [11] has been extended to newer cases and all patients were analyzed for the presence of ASXL1 and TET2 mutations. The extended group of 23 patients with phenotypic features consistent with RARS-T (Table 1) was subjected to MC and SNP-A analysis. All patients showed the presence of ring sideroblasts (>15%), some degree of reticulin fibrosis and varying degrees of thrombocytosis (>450 × 109/L). SNP-A facilitated detection of previously

Conflict of interest

None.

Acknowledgements

This work was supported by NIHR01 HL082983 (JPM), U54 RR019391 (JPM), K24 HL077522 (JPM), Award from AA & MDS International Foundation and a charitable donation from the Robert Duggan Cancer Research Fund.

Contributions. HS designed and performed molecular assays, wrote the manuscript; AMJ performed molecular assays and analyzed results; HM performed molecular assays, JB performed immunohistochemistry, NB classification of patients and database; EDH reviewed pathologic specimens, interpretation

References (30)

  • A. Renneville et al.

    High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis

    Leukemia

    (2006)
  • A.H. Schmitt-Graeff et al.

    JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

    Haematologica

    (2008)
  • A. Schmitt-Graeff et al.

    Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity

    Haematologica

    (2002)
  • Y. Pikman et al.

    MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

    PLoS Med

    (2006)
  • H. Szpurka et al.

    UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation

    Leukemia

    (2009)
  • Cited by (37)

    • Molecular genetics of MDS/MPN overlap syndromes

      2020, Best Practice and Research: Clinical Haematology
      Citation Excerpt :

      Representing the second most common molecular finding and accounting for the proliferative features of the disease, mutations in JAK2 are observed in over 50% of patients, with nearly half demonstrating comutation of SF3B1 and JAK2 [43,45–48]. In addition, somatic mutations of ASXL1, TET2, DNMT3A and SETBP1 occur in ~10–30% of patients, while MPL and CALR are observed in <5% of patients [43,45–48,51]. Notably, the majority of SF3B1 wild-type cases display comutation of JAK2 and ASXL1, as well as a separate spliceosome gene [46].

    • 5-hydroxymethylcytosine in cancer: Significance in diagnosis and therapy

      2015, Cancer Genetics
      Citation Excerpt :

      Of note, recurrent point mutations in TET1 have not been found in hematopoietic malignancies. In contrast, TET2 has been found to be mutated frequently in AML, secondary AML (sAML), myeloproliferative neoplasms (MPN), MDS, systemic mastocytosis, and CMML (Table 1) (9,78–89). Somatic mutations have been found in almost all of the TET2 exons.

    • The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes

      2015, Leukemia Research
      Citation Excerpt :

      Subsequent analysis has confirmed this finding, showing an overall frequency of ASXL1 mutation ranging from 14.4% to 20.7% of MDS. With the exception of refractory anemia with ring sideroblasts (RARS-T), higher frequencies (38–43%) appear to be associated with an MDS/MPN phenotype [64,65,68]. Clinically, ASXL1 mutations appear to be broadly adverse across many myeloid malignancies.

    • Perturbations of 5-Hydroxymethylcytosine Patterning in Hematologic Malignancies

      2013, Seminars in Hematology
      Citation Excerpt :

      Taken together, these studies illustrate that the TET enzymes play significant roles in stem cell development and differentiation. Although TET1 was identified as a fusion partner of the mixed lineage leukemia (MLL) gene in adult as well as pediatric leukemias bearing the t(10:11)(q22;q23) translocation,20–22 TET2 is mutated most frequently in AML, secondary AML (sAML), MPN, myelodysplastic syndrome (MDS), systemic mastocytosis, and chronic myelomonocytic leukemia (CMML)23–35 (Table 1). Somatic mutations have been found in almost all of the TET2 exons (Figure 3A).

    View all citing articles on Scopus
    View full text